The antiplatelet GPIIb/IIIa antibody, 7E3: A pioneer drug for the treatment of arterial thrombotic disorders
- 1 July 1994
- journal article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 3 (7) , 745-752
- https://doi.org/10.1517/13543784.3.7.745
Abstract
(1994). The antiplatelet GPIIb/IIIa antibody, 7E3: A pioneer drug for the treatment of arterial thrombotic disorders. Expert Opinion on Investigational Drugs: Vol. 3, No. 7, pp. 745-752. doi: 10.1517/13543784.3.7.745This publication has 27 references indexed in Scilit:
- Chimeric 7E3 prevents carotid artery thrombosis in cynomolgus monkeys.Stroke, 1994
- Contribution of platelets and the vessel wall to the antithrombotic effects of a single bolus injection of Fab fragments of the antiplatelet GPIIb/IIIa antibody 7E3 in a canine arterial eversion graft preparation.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994
- Secondary prevention of strokeThe Lancet, 1992
- Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery diseaseThe Lancet, 1990
- Antiplatelet monoclonal F(ab′)2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heartJournal of Molecular and Cellular Cardiology, 1989
- Secondary prevention of vascular disease by prolonged antiplatelet treatmentBMJ, 1988
- New Perspectives in Cell Adhesion: RGD and IntegrinsScience, 1987
- Aspirin as an Antithrombotic MedicationNew England Journal of Medicine, 1983
- Selective Cumulative Inhibition of Platelet Thromboxane Production by Low-dose Aspirin in Healthy SubjectsJournal of Clinical Investigation, 1982
- Platelet Membrane Defects in Glanzmann's ThrombastheniaJournal of Clinical Investigation, 1977